NCT06873997Completed
Real World Study of Bone Metastases in Patients with Advanced Breast Cancer
Analysis of the Occurrence Time of Bone Metastasis and Disease Treatment Patterns in Patients with Breast Cancer Bone Metastasis: a Retrospective Study from China
Source: ClinicalTrials.gov · Last updated 13 Mar 2025
Brief summary (registry, in English)
By analyzing the clinical data of patients with advanced breast cancer with bone metastasis admitted to our center from January 1, 2021 to February 28, 2023, this study aims to understand the real-world clinical diagnosis and treatment of breast cancer with bone metastasis, including the epidemiology of bone metastasis, screening and diagnosis methods, selection of clinical treatment methods, and occurrence of SRE. To explore the risk factors related to bone metastasis-free survival (BMFI). In addition, we will explore the use of quantitative analysis of CT values to evaluate bone metastases of breast cancer, aiming to provide a new method for imaging quantitative efficacy evaluation of bone metastases.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 737 (actual)
- First submitted
- 23 Feb 2025
- Start date
- 1 Jan 2021
- Primary completion date
- 1 Oct 2024
- Lead sponsor
- Zhejiang Cancer Hospital
- Diseases
- Metastatic breast cancer
- NCT number
- NCT06873997
What you commit to
- Study type: Observational
- Participants enrolled: 737
- From 1 Jan 2021 to the primary completion date, 1 Oct 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with other malignant tumors;
- History of hyperthyroidism and hypothyroidism, abnormal parathyroid function;
- History of bone metabolic diseases.
Other
- Exclusion is defined as meeting 1 of the following exclusion criteria:
Who the study is looking for
- Age ≥18y;
- Advanced breast cancer is clearly diagnosed;
- Imaging or pathology confirmed at least 1 bone metastasis;
- No history of other malignant tumors at the time of initial diagnosis;
- The physical status score of Eastern Tumor Collaboration Group (ECOG) was ≤2 points;
- Complete clinical and follow-up data.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Zhejiang Cancer Hospital Coordinator of this site? Confirm its status | Zhejiang | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.